Free Trial
NASDAQ:CADL

Candel Therapeutics (CADL) Stock Price, News & Analysis

Candel Therapeutics logo
$5.57 -0.08 (-1.42%)
Closing price 04/1/2025 04:00 PM Eastern
Extended Trading
$5.42 -0.16 (-2.78%)
As of 04:27 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Candel Therapeutics Stock (NASDAQ:CADL)

Key Stats

Today's Range
$5.40
$5.90
50-Day Range
$5.57
$12.21
52-Week Range
$1.56
$14.60
Volume
947,336 shs
Average Volume
2.70 million shs
Market Capitalization
$263.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.00
Consensus Rating
Buy

Company Overview

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Remove Ads

Candel Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
47th Percentile Overall Score

CADL MarketRank™: 

Candel Therapeutics scored higher than 47% of companies evaluated by MarketBeat, and ranked 620th out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Candel Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Candel Therapeutics has only been the subject of 4 research reports in the past 90 days.

  • Read more about Candel Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Candel Therapeutics are expected to grow in the coming year, from ($1.47) to ($1.15) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Candel Therapeutics is -3.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Candel Therapeutics is -3.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Candel Therapeutics has a P/B Ratio of 12.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Candel Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    9.98% of the float of Candel Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Candel Therapeutics has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Candel Therapeutics has recently increased by 3.29%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Candel Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Candel Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.98% of the float of Candel Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Candel Therapeutics has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Candel Therapeutics has recently increased by 3.29%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Candel Therapeutics has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Candel Therapeutics this week, compared to 3 articles on an average week.
  • Search Interest

    Only 18 people have searched for CADL on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.
  • MarketBeat Follows

    Only 7 people have added Candel Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Candel Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $633,534.00 in company stock.

  • Percentage Held by Insiders

    41.60% of the stock of Candel Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 13.93% of the stock of Candel Therapeutics is held by institutions.

  • Read more about Candel Therapeutics' insider trading history.
Receive CADL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Candel Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CADL Stock News Headlines

Trump to unlock 15-figure fortune for America (May 3rd) ?
We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men in America. Rickards has spent his fifty-year career in the innermost circles of the U.S. government and banking. And he believes Trump could soon release this frozen asset to the public.
Candel Therapeutics announces final survival data from CAN-2409 trial
See More Headlines

CADL Stock Analysis - Frequently Asked Questions

Candel Therapeutics' stock was trading at $8.68 at the beginning of 2025. Since then, CADL shares have decreased by 35.8% and is now trading at $5.57.
View the best growth stocks for 2025 here
.

Candel Therapeutics, Inc. (NASDAQ:CADL) issued its earnings results on Thursday, March, 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.23) by $0.17.

Candel Therapeutics (CADL) raised $72 million in an initial public offering (IPO) on Tuesday, July 27th 2021. The company issued 9,000,000 shares at $8.00 per share. Jefferies, Credit Suisse, BMO Capital Markets and UBS Investment Bank served as the underwriters for the IPO.

Shares of CADL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Candel Therapeutics investors own include Advanced Micro Devices (AMD), Netflix (NFLX), NVIDIA (NVDA), Tesla (TSLA), Alphabet (GOOG), Meta Platforms (META) and Visa (V).

Company Calendar

Last Earnings
3/13/2025
Today
4/02/2025
Next Earnings (Estimated)
5/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CADL
Fax
N/A
Employees
60
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$21.00
High Stock Price Target
$25.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+277.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-37,940,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$120,000.00
Price / Cash Flow
N/A
Book Value
$0.44 per share
Price / Book
12.66

Miscellaneous

Free Float
18,966,000
Market Cap
$263.10 million
Optionable
Optionable
Beta
-1.29
Unlock the Potential in Options Trading Cover

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report

This page (NASDAQ:CADL) was last updated on 4/2/2025 by MarketBeat.com Staff
From Our Partners